{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 25,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a split-column layout to contrast two phases of a clinical trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/13",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.25,
        "y": 0.83
      },
      "kind": "callout",
      "text": "Initial Phase 1b Data Read-Out Expected in 1Q2024",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b4d88b9-08ff-478c-b8fa-3f5379d73f0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.48,
        "x": 0.5,
        "y": 0.28
      },
      "kind": "list",
      "text": "Phase 1b: Dose Expansion - Enrolling. Patients in the target population - 2 cohorts of 20-25 patients, 2 dosing regimens (50 mg and 75 mg QD). Primary objectives: Establish RP2D. Key Endpoints: Preliminary Efficacy, Safety, Pharmacokinetics and Pharmacodynamics",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92eb5b9f-68f4-47c6-a83f-357cafe40647",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.48,
        "x": 0.02,
        "y": 0.28
      },
      "kind": "list",
      "text": "Phase 1a: Dose Escalation - Completed. Patients with advanced solid tumors (all comers). Primary Objectives: Select doses/schedules for Phase 1b. Key Endpoints: Assess Pharmacokinetics, pharmacodynamics, lab abnormalities, dose limiting toxicities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c44978cd-0769-4c8f-984c-b8091b5a113f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.35,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Clinicaltrials.gov NCT05226507",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5528c51c-fcee-426b-a32e-593a5e7e16a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Enrolling patients with platinum-resistant, ARID1A-mutated ovarian cancer (target population) a",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9668a14-23c5-4a16-8d8b-6ae0d1b522f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.3,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "a. Fast Track Designation granted for platinum resistant, ARID1A-mutated ovarian carcinoma,",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "105975c0-0718-4ed9-9634-ea5726efa55e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXP800: Phase 1b Underway, Fast Track Designation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4a00e4a-d6c6-483e-9d8c-95e007e3c858",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 13,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
      "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
      "position": 1,
      "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}